H2AX phosphorylation regulated by p38 is involved in Bim expression and apoptosis in chronic myelogenous leukemia cells induced by imatinib

Apoptosis

Volumn 19, Issue 8, 2014, Pages 1281-1292

  Dong, Yaqiong ^a,b   Xiong, Min ^a   Duan, Lianning ^a   Liu, Ze ^c   Niu, Tianhui ^a   Luo, Yuan ^a   Wu, Xinpin ^a   Xu, Chengshan ^a   Lu, Chengrong ^a  

^a AIR FORCE GENERAL HOSPITAL   (China)

^b HEBEI NORTH UNIVERSITY   (China)

^c NANKAI UNIVERSITY   (China)

Author keywords

Apoptosis; Bim; Chronic myelogenous leukemia; H2AX phosphorylation

Indexed keywords

BIM PROTEIN; HISTONE H2AX; HISTONE H3; IMATINIB; MITOGEN ACTIVATED PROTEIN KINASE P38; STRESS ACTIVATED PROTEIN KINASE 1; ANTINEOPLASTIC AGENT; APOPTOSIS REGULATORY PROTEIN; BCL-2-LIKE PROTEIN 11; BENZAMIDE DERIVATIVE; H2AFX PROTEIN, HUMAN; HISTONE; MEMBRANE PROTEIN; ONCOPROTEIN; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE;

APOPTOSIS; ARTICLE; CHRONIC MYELOID LEUKEMIA; ENZYME ACTIVATION; GENE CONTROL; GENE OVEREXPRESSION; LEUKEMIA CELL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; CELL PROLIFERATION; DRUG EFFECTS; DRUG RESISTANCE; GENETIC EPIGENESIS; GENETICS; HUMAN; K562 CELL LINE; METABOLISM; PATHOLOGY; PHOSPHORYLATION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BENZAMIDES; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; EPIGENESIS, GENETIC; HISTONES; HUMANS; K562 CELLS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MEMBRANE PROTEINS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PIPERAZINES; PROTO-ONCOGENE PROTEINS; PYRIMIDINES;

EID: 84904250832     PISSN: 13608185     EISSN: 1573675X     Source Type: Journal    
DOI: 10.1007/s10495-014-0997-9     Document Type: Article

References (35)

1. Goldman JM, Melo JV (2001) Targeting the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344: 1084-1086 (Pubitemid 32267980)
2. Goldman JM, Melo JV (2003) Chronic myeloid leukemia- advances in biology and new approaches to treatment. N Engl J Med 349:1451-1464 (Pubitemid 37211061)
3. Brauer KM, Werth D, von Schwarzenberg K, Bringmann A, Kanz L, Grunebach F (2007) BCR-ABL activity is critical for the immunogenicity of chronic myelogenous leukemia cells. Cancer Res 67:5489-5497 (Pubitemid 46997290)
4. Zhang YJ, Lu CR, Cao Y, Luo Y, Bao RF, Yan S et al (2013) Imatinib induces H2AX phosphorylation and apoptosis in chronic myelogenous leukemia cells in vitro via caspase-3/Mst1 pathway. Acta Pharmacol Sin 33:551-557
5. Dumka D, Puri P, Carayol N, Lumby C, Balachandran H, Schuster K et al (2009) Activation of the p38 Map kinase pathway is essential for the antileukemic effects of dasatinib. Leuk Lymphoma 50:2017-2029
6. Strout MP, Schatz DG (2009) Imatinib resistance and progression of CML to blast crisis: somatic hypermutation AIDing the way. Cancer Cell 16:174-176
7. Lu Z, Jin Y, Chen C, Li J, Cao Q, Pan J (2010) Pristimerin induces apoptosis in imatinib-resistant chronic myelogenous leukemia cells harboring T315I mutation by blocking NF-kappaB signaling and depleting Bcr-Abl. Mol Cancer 9:112
8. Klemm L, Duy C, Iacobucci I, Kuchen S, von LG, Feldhahn N et al (2009) The B cell mutator AID promotes B lymphoid blast crisis and drug resistance in chronic myeloid leukemia. Cancer Cell 16:232-245
9. Deguchi Y, Kimura S, Ashihara E, Niwa T, Hodohara K, Fujiyama Y et al (2008) Comparison of imatinib, dasatinib, nilotinib and INNO-406 in imatinib-resistant cell lines. Leuk Res 32:980-983
10. Nicolini FE, Basak GW, Soverini S, Martinelli G, Mauro MJ, Muller MC et al (2011) Allogeneic stem cell transplantation for patients harboring T315I BCR-ABL mutated leukemias. Blood 118:5697-5700
11. Nicolini FE, Ibrahim AR, Soverini S, Martinelli G, Muller MC, Hochhaus A et al (2013) The BCR-ABLT315I mutation compromises survival in chronic phase chronic myelogenous leukemia patients resistant to tyrosine kinase inhibitors, in a matched pair analysis. Haematologica 98:1510-1516
12. Stiff T, O'Driscoll M, Rief N, Iwabuchi K, Lobrich M, Jeggo PA (2004) ATM and DNA-PK function redundantly to phosphorylate H2AX after exposure to ionizing radiation. Cancer Res 64:2390-2396 (Pubitemid 38523891)
13. Falck J, Coates J, Jackson SP (2005) Conserved modes of recruitment of ATM, ATR and DNA-PKcs to sites of DNA damage. Nature 434:605-611 (Pubitemid 40488547)
14. Liu Y, Parry JA, Chin A, Duensing S, Duensing A (2008) Soluble histone H2AX is induced by DNA replication stress and sensitizes cells to undergo apoptosis. Mol Cancer 7:61
15. Cook PJ, Ju BG, Telese F, Wang X, Glass CK, Rosenfeld MG (2009) Tyrosine dephosphorylation of H2AX modulates apoptosis and survival decisions. Nature 458:591-596
16. Lu C, Zhu F, Cho YY, Tang F, Zykova T, Ma WY et al (2006) Cell apoptosis: requirement of H2AX in DNA ladder formation, but not for the activation of caspase-3. Mol Cell 23:121-132 (Pubitemid 43963445)
17. Lu C, Xiong M, Luo Y, Li J, Zhang Y, Dong Y et al (2013) Genome-wide transcriptional analysis of apoptosis-related genes and pathways regulated by H2AX in lung cancer A549 cells. Apoptosis 18:1039-1047
18. Dickey JS, Redon CE, Nakamura AJ, Baird BJ, Sedelnikova OA, Bonner WM (2009) H2AX: functional roles and potential applications. Chromosoma 118:683-692
19. Walsh SH, Rosenquist R (2005) Absence of H2AX gene mutations in B-cell leukemias and lymphomas. Leukemia 19:464
20. Liu Y, Tseng M, Perdreau SA, Rossi F, Antonescu C, Besmer P et al (2007) Histone H2AX is a mediator of gastrointestinal stromal tumor cell apoptosis following treatment with imatinib mesylate. Cancer Res 67:2685-2692 (Pubitemid 46548956)
21. Nagamachi A, Yamasaki N, Miyazaki K, Oda H, Miyazaki M, Honda Z et al (2009) Haploinsufficiency and acquired loss of Bcl11b and H2AX induces blast crisis of chronic myelogenous leukemia in a transgenic mouse model. Cancer Sci 100: 1219-1226
22. Bassing CH, Suh H, Ferguson DO, Chua KF, Manis J, Eckersdorff M et al (2003) Histone H2AX: a dosage-dependent suppressor of oncogenic translocations and tumors. Cell 114:359-370 (Pubitemid 36962934)
23. Puissant A, Grosso S, Jacquel A, Belhacene N, Colosetti P, Cassuto JP et al (2008) Imatinib mesylate-resistant human chronic myelogenous leukemia cell lines exhibit high sensitivity to the phytoalexin resveratrol. FASEB J 22:1894-1904 (Pubitemid 351811466)
24. Li P, Nijhawan D, Wang X (2004) Mitochondrial activation of apoptosis. Cell 116:S57-S59
25. Thomson S, Clayton AL, Hazzalin CA, Rose S, Barratt MJ, Mahadevan LC (1999) The nucleosomal response associated with immediate-early gene induction is mediated via alternative MAP kinase cascades: MSK1 as a potential histone H3/HMG-14 kinase. EMBO J 18:4779-4793 (Pubitemid 29415531)
26. Shimada M, Nakadai T, Fukuda A, Hisatake K (2010) cAMP-response element-binding protein (CREB) controls MSK1-mediated phosphorylation of histone H3 at the c-fos promoter in vitro. J Biol Chem 285:9390-9401
27. Atsumi Y, Inase A, Osawa T, Sugihara E, Sakasai R, Fujimori H et al (2013) The Arf/p53 protein module, which induces apoptosis, down-regulates histone H2AX to allow normal cells to survive in the presence of anti-cancer drugs. J Biol Chem 288:13269-13277
28. Gillings AS, Balmanno K, Wiggins CM, Johnson M, Cook SJ (2009) Apoptosis and autophagy: BIM as a mediator of tumour cell death in response to oncogene-targeted therapeutics. FEBS J 276:6050-6062
29. Kuribara R, Honda H,Matsui H, Shinjyo T, Inukai T, Sugita K et al (2004) Roles of Bim in apoptosis of normal and Bcr-Abl-expressing hematopoietic progenitors. Mol Cell Biol 24:6172-6183 (Pubitemid 38891120)
30. Jia HY, Wu JX, Zhu XF, Chen JM, Yang SP, Yan HJ et al (2009) ZD6474 inhibits Src kinase leading to apoptosis of imatinibresistant K562 cells. Leuk Res 33:1512-1519
31. Youle RJ, Strasser A (2008) The BCL-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol 9:47-59
32. Bartova E, Krejci J, Harnicarova A, Galiova G, Kozubek S (2008) Histone modifications and nuclear architecture: a review. J Histochem Cytochem 56:711-721 (Pubitemid 351991084)
33. Schuler M, Maurer U, Goldstein JC, Breitenbucher F, Hoffarth S, Waterhouse NJ et al (2003) p53 triggers apoptosis in oncogene-expressing fibroblasts by the induction of Noxa and mitochondrial Bax translocation. Cell Death Differ 10:451-460 (Pubitemid 36626357)
34. Beaujean N (2014) Histone post-translational modifications in preimplantation mouse embryos and their role in nuclear architecture. Mol Reprod Dev 81:100-112
35. Zhang C, Gao S, Molascon AJ, Liu Y, Andrews PC (2014) Quantitative Proteomics Reveals Histone Modifications in Crosstalk with H3 Lysine 27 Methylation. Mol Cell Proteomics 13:749-759